Category: Pα+ - Page 10 - Psychedelic Alpha

Read more about the article Pα+ Psychedelic Bulletin #160: Mutual Recognition for MDMA-AT in the UK? Beckley Shares Cut of 5-MeO-DMT Data; and more

Pα+ Psychedelic Bulletin #160: Mutual Recognition for MDMA-AT in the UK? Beckley Shares Cut of 5-MeO-DMT Data; and more

Post published:March 29, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article ICER Draft Evidence Report on Lykos’ MDMA-Assisted Psychotherapy Deems Clinical Evidence “Insufficient”

ICER Draft Evidence Report on Lykos’ MDMA-Assisted Psychotherapy Deems Clinical Evidence “Insufficient”

Post published:March 27, 2024
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #159: Patient Access to MDMA-Assisted Therapy; Notes from SXSW; Whole Mushroom vs. Synthetic Psilocybin

Pα+ Psychedelic Bulletin #159: Patient Access to MDMA-Assisted Therapy; Notes from SXSW; Whole Mushroom vs. Synthetic Psilocybin

Post published:March 21, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Fluence’s Elizabeth Nielson on Professional Education for the Psychedelics Field

Fluence’s Elizabeth Nielson on Professional Education for the Psychedelics Field

Post published:March 19, 2024
Post category:Interviews Pα+

Read more about the article Gilgamesh Scoops $14m from NIDA to Develop Safer Ibogaine Analog for Opioid Use Disorder

Gilgamesh Scoops $14m from NIDA to Develop Safer Ibogaine Analog for Opioid Use Disorder

Post published:March 14, 2024
Post category:Analysis News Pα+

Read more about the article Cybin Scores Breakthrough Therapy Designation for Deuterated Psilocybin Analog in MDD, Shares 4-Month Data

Cybin Scores Breakthrough Therapy Designation for Deuterated Psilocybin Analog in MDD, Shares 4-Month Data

Post published:March 13, 2024
Post category:Analysis News Pα+

Read more about the article FDA Hands MindMed’s LSD Candidate Breakthrough Therapy Designation in Generalised Anxiety Disorder; Company Provides 12-Week Data and Fleshes Out Phase 3 Program Plans

FDA Hands MindMed’s LSD Candidate Breakthrough Therapy Designation in Generalised Anxiety Disorder; Company Provides 12-Week Data and Fleshes Out Phase 3 Program Plans

Post published:March 7, 2024
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #158: Fluence Brings Psychedelic Therapy Training to Ukraine; MindBio’s Microdosing Readout; Biomind’s 5-MeO-DMT Study; and more…

Pα+ Psychedelic Bulletin #158: Fluence Brings Psychedelic Therapy Training to Ukraine; MindBio’s Microdosing Readout; Biomind’s 5-MeO-DMT Study; and more…

Post published:March 6, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Prominent At-Home Ketamine Co. Founder, Juan Pablo Cappello, Sounds Alarm, Withdraws Support for the Practice

Prominent At-Home Ketamine Co. Founder, Juan Pablo Cappello, Sounds Alarm, Withdraws Support for the Practice

Post published:March 4, 2024
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #157: Psilocybin for Generalised Anxiety Disorder; Uptick in Psilocybin-Related Poison Centre Calls

Pα+ Psychedelic Bulletin #157: Psilocybin for Generalised Anxiety Disorder; Uptick in Psilocybin-Related Poison Centre Calls

Post published:March 1, 2024
Post category:Psychedelic Bulletin Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.